Description

You know innovation costs billions, but did you know most clinical trials still fail?
For executives watching capital markets, biotech investing, and long‑term innovation, understanding why drugs rarely make it from discovery to market is a competitive advantage. In this episode, Dan Pascone talks with Suzanne Vyvoda, founder of Concordia BioStrategies and seasoned biotech operator, to unpack the real economics and operational reality behind clinical trials, drug development, and what actually makes a program investable, even in a tight funding market.

In this episode you’ll learn:

• Why clinical trials are so expensive and why most never succeed
• How operational strategy separates winners from survivors
• What makes a biotech company investable beyond science alone
• How human behavior and real patients influence outcomes
• Lessons from a rapid ~$7B exit and how that shaped Suzanne’s approach
• Why bringing ops into strategy early can drive value and de‑risk capital
• Suzanne’s mission to mentor and invest in talented leaders, especially women, in life sciences

Whether you’re an investor, executive, founder, or leader evaluating long‑cycle innovation, this episode brings clarity, context, and strategy to a world often hidden behind jargon, volatility, and long timelines.

Featuring: Dan Pascone & Suzanne Vyvoda

🧠 Explore more insights: www.makingsenseofyourmoney.com

#MakingSensePodcast #Biotech #ClinicalTrials #LifeSciences #DrugDevelopment #BiotechInvesting #Pharma #ConcordiaBioStrategies #SuzanneVyvoda #InnovationStrategy #HealthcareVC #OperationalExcellence #ExecutiveEducation #LongGameInvesting #TailoredWealth #DanPascone